← FDA DRUG APPROVALS

FDA ANDA · ANDA211663

EZETIMIBE AND SIMVASTATIN

Sponsor: SCIEGEN PHARMS

APPLICATION
ANDA211663
TYPE
ANDA
ORIGINAL APPROVAL
2024-12-10
LATEST ACTION
2024-12-10
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

EZETIMIBE AND SIMVASTATINDiscontinued
EZETIMIBE 10MG, SIMVASTATIN 40MG · TABLET · ORAL
EZETIMIBE AND SIMVASTATINDiscontinued
EZETIMIBE 10MG, SIMVASTATIN 10MG · TABLET · ORAL
EZETIMIBE AND SIMVASTATINDiscontinued
EZETIMIBE 10MG, SIMVASTATIN 80MG · TABLET · ORAL
EZETIMIBE AND SIMVASTATINDiscontinued
EZETIMIBE 10MG, SIMVASTATIN 20MG · TABLET · ORAL

Approval history

2024-12-10UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →